Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Input: Consider Input: Paragraph: Measles has killed nearly three times as many people in Congo than an Ebola outbreak in the country that has garnered far more international attention, particularly after health teams came under attack from armed militias operating in the area. “Lack of funding remains a huge impediment to successfully curbing the outbreak,” WHO said in announcing its appeal. While $27.6 million already has been mobilized to curb the measles epidemic, WHO said that $40 million is needed for a special six-month plan to vaccinate older children between the ages of 6 and 14. A vaccine against measles has existed for decades but some 310,000 cases have been reported in Congo since the beginning of 2019. Health workers in Congo struggle to access remote parts of the vast country, and vaccination rates remain low in areas where armed groups operate. Many health resources in Congo this year also have been devoted to the simultaneous outbreak of Ebola, which has become the second worst in history after the 2014-2016 West Africa epidemic. At least 2,231 people have died of Ebola since that outbreak was first identified in August 2018. Claim: WHO: Death toll from measles outbreak in Congo hits 6,000.

Output: The death toll from a measles epidemic in Congo has surpassed 6,000, the World Health Organization said Tuesday as it warned that more funds are needed to save lives during the world’s worst outbreak of the infectious disease.


Input: Consider Input: Paragraph: "The cost of the drug wasn’t mentioned – a big oversight. Other news stories pegged it at about $35,000 a year. Adequate job. The story explained: ""But experts stress that Benlysta is not a miracle drug: It only worked in 35 percent of North American patients tested and was not effective for patients with the deadliest form of the disease. Additionally, it did not show positive results in African Americans, who are disproportionately affected by lupus."" There was no discussion of harms. An NPR story, by comparison, pointed out that ""There are side effects, of course, and some of them are pretty serious. In clinical tests involving about 2,100 people, 11 taking Benlysta died compared with 4 getting placebo. About 6 percent of people taking Benlysta got serious infections compared with 5.2 percent on placebo."" The story offered an interesting historical perspective on the evidence: ""The company originally tested Benlysta, known generically as belimumab, as a treatment for rheumatoid arthritis. When a mid-stage trial in lupus patients failed to meet researchers’ goals in 2006, many analysts wrote the drug off and downgraded the company’s stock. But when scientists reanalyzed the data they found that the drug helped block the antibodies that cause lupus symptoms in a subset of patients."" No disease mongering of lupus. Two independent sources were quoted. Not applicable. With no other new drug approved for lupus in 56 years, there’s not been much to compare it with. The story did state that some experts thought this ""could prompt development of other drugs that are even more effective in treating the debilitating immune system disorder."" The focus of the story is FDA approval of the new drug. The headline explains that the FDA approved the first new drug for lupus in 56 years. It’s clear the story did not rely solely on a news release." Claim: FDA approves first new drug for lupus in 56 years

Output: "Good caveats, including in the patient profiled, who said, ""It’s a bittersweet thing for me because I have friends with lupus for whom this drug won’t work. There’s no one-size-fits-all for lupus and I’m just extremely fortunate that my lupus is mild and is helped by Benlysta."" The story should have discussed potential harms and costs. As the story explained, this was not only the first new lupus drug approved in 56 years, but it could be ""a milestone that medical experts say could prompt development of other drugs that are even more effective in treating the debilitating immune system disorder."""


Input: Consider Input: Paragraph: Only a fraction of Kenya’s estimated 100,000 healthcare workers had received any instruction in how to protect themselves, Seth Panyako, the secretary general of the Kenya National Union of Nurses, told Reuters. Government spokesman Cyrus Oguna said he would check into the reports of the training and protective gear shortages. Kenya had reported 28 cases of the coronavirus and one death as of Friday. The virus has so far been multiplying across Africa more slowly than in Asia or Europe - but the World Health Organization has warned the continent’s window to curb the infection is narrowing every day. Nurses in the western Kenyan town of Kakamega and the coastal town of Kilifi ran away when patients with coronavirus symptoms came to their hospitals over the past two weeks, Panyako said on Thursday. Nurses at Nairobi’s Mbagathi County Hospital went on a go-slow protest last week in protest at a lack of protective gear and training. They feared catching the disease and infecting their families, Panyako said. “The government is not taking it seriously when health workers run away,” he said. “My clear message to the government ... give them the protective equipment they need.”  Panyako, whose union represents 30,000 health workers, said he had only heard of 1,200 staff getting training in how to protect themselves. A host of initiatives have sprung up to fill the gaps. Kenyan start-up Rescue.co, whose Flare app functions as the Uber for private ambulances in Kenya, last week began offering training and protective equipment for the 600 nurses and paramedics using its network. One paramedic on a course told Reuters he had previously refused to attend a suspected coronavirus patient because he did not have training. “The team was scared so we didn’t go,” he said, declining to give his name. Caitlin Dolkart, who co-founded rescue.co, said her company had applied for government permission for trained paramedics to carry out coronavirus tests in patients’ homes. “They are on the frontlines of responding to patients,” she said. “They have to be protected.” Claim: Some Kenyan nurses refuse coronavirus patients in protest over shortages: union.


Output: Nurses in Kenya’s capital and at least two towns have launched protests or refused to treat suspected coronavirus patients because the government has not given them enough protective gear or training, a medical union chief said.